RANTES release by human airway smooth muscle: effects of prostaglandin E(2) and fenoterol.
In human airway smooth muscle cells, the levels of RANTES were increased upon stimulation with interleukin-1beta together with tumour necrosis factor-alpha (TNF-alpha) (10 ng ml(-1) for each). In this study, we have assessed the effects of prostaglandin E(2) and the beta(2)-adrenoceptor agonist, fenoterol on RANTES (regulated upon activation, normal T cell expressed and secreted) release by these cells. The levels of RANTES released by human airway smooth muscle cells were measured after 24 h of treatment. Prostaglandin E(2) and fenoterol, only in presence of a cyclo-oxygenase inhibitor indomethacin (10(-6) M), provoked a concentration-dependent reduction in RANTES release. These data suggest that, in settings where cyclo-oxygenase activity is low, both drugs may relieve the symptoms of airway diseases by reducing RANTES production.
Lazzeri
N
N
Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK.
Belvisi
M G
MG
Patel
H J
HJ
Chung
K F
KF
Yacoub
M H
MH
Mitchell
J A
JA
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D018946:Chemokine CCL5 / Q000096:biosynthesis*; D000242:Cyclic AMP / Q000502:physiology; D015232:Dinoprostone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005280:Fenoterol / Q000494:pharmacology*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000187:drug effects* / Q000378:metabolism; D014132:Trachea / Q000187:drug effects* / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D018946:Chemokine CCL5; D005280:Fenoterol; D000242:Cyclic AMP; D015232:Dinoprostone; D007213:Indomethacin